Pharma investments blocked by health regulator’s lack of analysts
ANVISA has about R$6bn in new drugs waiting for analysis and another R$11bn under consideration 04/22/2024 Ricardo Cappelli — Foto: Gesival Nogueira Kebec/Valor The pharmaceutical industry has nearly R$6 billion in potential investments pending analysis by the National Health Surveillance Agency (ANVISA). Another R$11 billion is being analyzed, but there has been no response so […]
